Participated · Series B · Sep 2023

Tribun Health’s core product is CaloPix®, an image-management platform that provides a digital alternative to traditional microscopy for anatomopathology. The company is advancing its Pathomix® project to broaden diagnostic product offerings and foster integration between healthcare services, research and pharmaceutical development. Pathomix® focuses on tools to consolidate, enhance, and exploit real-world histopathological and clinical data, including an advanced data query module for secondary use while adhering to GDPR and HIPAA. The project aims to ensure data interoperability and streamline connections between CaloPix® users (predominantly pathologists) and stakeholders involved in multicenter R&D. Tribun Health intends to leverage its existing CaloPix® customer network to automate extraction and export of data to support pharmaceutical laboratories and AI companies in assembling uniform cohorts for precision medicine. The company received public funding support that strengthens its market position amid global competition. Tribune Health provides laboratories and pharmaceutical organizations with a modular, end-to-end computational pathology platform that leverages AI for diagnosis, prognosis and drug development. Its platform is designed to empower physicians to deliver personalized and timely therapies and to help researchers accelerate development of new therapies. The company is led by CEO Jean-François Pomerol and is based in Paris, France. Tribune Health will use the new capital to expand sales and marketing activities in Europe and North America, bolster development efforts, and scale deployment resources to meet growing demand from hospitals and private labs. The funds also financed the recent acquisition of Keen Eye and will support enhancements to the Keen Eye EyeDo computational pathology platform to exploit secondary use of real-world oncology data for pharmaceutical and biotech purposes.

Participated · Series A · Jan 2022

Resilience offers a comprehensive remote patient care solution dedicated to cancer patients and healthcare professionals, combining a mobile application with a remote patient monitoring platform. The mobile app helps individuals affected by cancer manage treatment-related side effects and foster self-care. The monitoring platform enables healthcare professionals to better understand and improve patient care and the overall care pathway. The company raised $25M to accelerate deployment of its solution in France and abroad. Resilience plans to leverage the rapid adoption of medical remote monitoring in France and the regulatory agency’s validation of its clinical value to scale internationally. Founded in February 2021 by Céline Lazorthes, Jonathan Benhamou, and Gustave Roussy and based in Paris, the company partners with more than 90 centers and supports over 10,000 patients. Resilience provides a patient app for tracking symptoms, side effects and other data points and a software-as-a-service platform that lets hospitals use that data to personalize cancer treatments. The company was founded in partnership with Gustave Roussy and aims to better support both patients and caregivers throughout lengthy cancer care journeys. Resilience emphasizes helping practitioners overcome blindspots and adapt care more quickly rather than replacing doctors. The startup acquired Betterise to accelerate its data-driven cancer care capabilities. Its long-term vision is to improve outcomes and quality of life for people diagnosed with cancer by combining patient-reported data, clinical workflows and content. Financially, Resilience recently closed a $45 million Series A to scale its product and partnerships. Resilience is building a full-stack software solution for cancer care that serves both medical teams and patients. For practitioners the company offers a SaaS product to augment therapeutic decisions by categorizing scientific literature, using machine learning to find similarities with past cases, and surfacing relevant clinical trials. For patients it provides a web and mobile app that explains treatments, helps manage side effects, collects patient-reported data, and aims to improve quality of life. The company is assembling a data science team to use natural language processing on scientific literature and is partnering with hospitals to access past-case data; a medical team will double-check outputs. Resilience positions itself as mission-driven with a scientific board, a patient board, and Gustave Roussy acting as a co-founder. The startup has raised $6 million (€5 million) in a funding round led by Singular.